KR20230135569A - 인플루엔자 a 바이러스에 대한 항체 - Google Patents

인플루엔자 a 바이러스에 대한 항체 Download PDF

Info

Publication number
KR20230135569A
KR20230135569A KR1020237021213A KR20237021213A KR20230135569A KR 20230135569 A KR20230135569 A KR 20230135569A KR 1020237021213 A KR1020237021213 A KR 1020237021213A KR 20237021213 A KR20237021213 A KR 20237021213A KR 20230135569 A KR20230135569 A KR 20230135569A
Authority
KR
South Korea
Prior art keywords
antibody
antigen
binding fragment
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237021213A
Other languages
English (en)
Korean (ko)
Inventor
다비드 코르티
마테오 사무엘 피주토
파브리지아 자타
엘리자베타 카메로니
기오르기 스넬
Original Assignee
비르 바이오테크놀로지, 인코포레이티드
후맙스 바이오메드 에스에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비르 바이오테크놀로지, 인코포레이티드, 후맙스 바이오메드 에스에이 filed Critical 비르 바이오테크놀로지, 인코포레이티드
Publication of KR20230135569A publication Critical patent/KR20230135569A/ko
Pending legal-status Critical Current

Links

Classifications

    • C07K16/1018—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020237021213A 2020-11-23 2021-11-19 인플루엔자 a 바이러스에 대한 항체 Pending KR20230135569A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063117437P 2020-11-23 2020-11-23
US63/117,437 2020-11-23
US202063123419P 2020-12-09 2020-12-09
US63/123,419 2020-12-09
PCT/US2021/060123 WO2022109291A1 (en) 2020-11-23 2021-11-19 Antibodies against influenza a viruses

Publications (1)

Publication Number Publication Date
KR20230135569A true KR20230135569A (ko) 2023-09-25

Family

ID=79021185

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237021213A Pending KR20230135569A (ko) 2020-11-23 2021-11-19 인플루엔자 a 바이러스에 대한 항체

Country Status (10)

Country Link
US (1) US20240317841A1 (https=)
EP (1) EP4247844A1 (https=)
JP (1) JP2023551666A (https=)
KR (1) KR20230135569A (https=)
AU (1) AU2021382620A1 (https=)
CA (1) CA3197537A1 (https=)
IL (1) IL302938A (https=)
MX (1) MX2023005653A (https=)
TW (1) TWI901812B (https=)
WO (1) WO2022109291A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023230448A1 (en) * 2022-05-23 2023-11-30 Vir Biotechnology, Inc. Combination immunotherapy for influenza
WO2024081639A1 (en) * 2022-10-11 2024-04-18 Seawolf Therapeutics, Inc. Novel lipid nanoparticle compositions for the delivery of nucleic acids

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
JP3051957B2 (ja) 1997-08-28 2000-06-12 榮太郎 清水 融雪機
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
ATE492562T1 (de) 2003-09-24 2011-01-15 Kyowa Hakko Kirin Co Ltd Rekombinanter antikörper gegen humanen insulin- like growth factor
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8119772B2 (en) 2006-09-29 2012-02-21 California Institute Of Technology MART-1 T cell receptors
CA2807664A1 (en) * 2010-08-12 2012-02-16 Theraclone Sciences, Inc. Anti-hemagglutinin antibody compositions and methods of use thereof
WO2012054745A1 (en) * 2010-10-20 2012-04-26 New York Blood Center, Inc. Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection
TW201806968A (zh) * 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
US9908930B2 (en) * 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
US10519251B2 (en) 2013-12-30 2019-12-31 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
TWI702229B (zh) * 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
MY186585A (en) * 2015-02-05 2021-07-28 Janssen Vaccines & Prevention Bv Binding molecules directed against influenza hemagglutinin and uses thereof
EP3294774B1 (en) 2015-05-13 2024-08-28 Zumutor Biologics, Inc. Afucosylated protein, cell expressing said protein and associated methods
WO2017192589A1 (en) * 2016-05-02 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to influenza ha and their use and identification
WO2019024979A1 (en) 2017-07-31 2019-02-07 Institute For Research In Biomedicine FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION
AU2018334886B2 (en) 2017-09-22 2025-06-26 WuXi Biologics Ireland Limited Novel bispecific polypeptide complexes
US11780907B2 (en) * 2018-01-26 2023-10-10 Regeneron Pharmaceuticals, Inc. Human antibodies to influenza hemagglutinin

Also Published As

Publication number Publication date
WO2022109291A1 (en) 2022-05-27
AU2021382620A9 (en) 2024-04-18
IL302938A (en) 2023-07-01
MX2023005653A (es) 2023-07-31
AU2021382620A1 (en) 2023-06-15
CA3197537A1 (en) 2022-05-27
TW202235103A (zh) 2022-09-16
US20240317841A1 (en) 2024-09-26
TWI901812B (zh) 2025-10-21
EP4247844A1 (en) 2023-09-27
JP2023551666A (ja) 2023-12-12

Similar Documents

Publication Publication Date Title
RS64645B1 (sr) Antitela protiv sars-cov-2
JP2023523549A (ja) ＳＡＲＳ－ＣｏＶ－２に対する抗体およびそれを使用する方法
WO2022204202A1 (en) Antibodies that bind to multiple sarbecoviruses
US20240092876A1 (en) Broadly neutralizing antibodies against influenza neuraminidase
US20240141021A1 (en) Anti-influenza antibodies and combinations thereof
TWI901812B (zh) 針對a型流感病毒的抗體
KR20250030975A (ko) 인플루엔자 뉴라미니다제에 대한 광범위 중화 항체
WO2023230448A1 (en) Combination immunotherapy for influenza
TW202417477A (zh) 與多種嚴重急性呼吸道症候群β型冠狀病毒結合之抗體
JP2025526405A (ja) Ｒｓｖ及びｍｐｖパラミクソウイルスに対する広域中和抗体
EA051192B1 (ru) Антитела против вирусов гриппа а
CN116981687A (zh) 针对甲型流感病毒的抗体
CN116997567A (zh) 抗流感抗体和其组合
CN116888157A (zh) 针对流感神经氨酸苷酶的广泛中和抗体
WO2025015321A1 (en) Broadly neutralizing antibodies against rsv and mpv paramyxoviruses
WO2024118998A2 (en) Engineered anti-sars-cov-2 antibodies and methods of using the same
WO2023245078A1 (en) Anti-parvovirus antibodies and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000